IFF vs INGR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: INGR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IFF and INGR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IFF and INGR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. The company traces to 1833 and reached its current scale through the 2018 Frutarom acquisition and the February 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division, a roughly $26 billion combination that made IFF one of the four global ingredient houses alongside Givaudan, dsm-firmenich and Symrise. As of the second quarter of 2026 it reports three continuing segments, Taste (~$688 million of quarterly sales), Health & Biosciences (~$601 million) and Scent (~$665 million), after moving the Food Ingredients and Soy Crush businesses into discontinued operations.

Full IFF guide

Ingredion Incorporated grinds corn and other crops into starches, sweeteners and texturizing ingredients that end up inside packaged food, beverages, paper and pharmaceuticals. The business reports in three segments: Texture & Healthful Solutions, the global specialty texturant arm that produced ~$627 million of second quarter net sales; Food and Industrial Ingredients in Latin America, at ~$611 million; and Food and Industrial Ingredients in the US and Canada, at ~$488 million. A fourth bucket called All Other holds the PureCircle stevia, sugar reduction and pea protein fortification businesses. Trailing twelve month revenue runs about ~$7.2 billion on a market capitalisation near ~$6.6 billion, and the company has been reshaping the portfolio hard, closing its Cabo plant in Brazil and selling ~51% of its Pakistan subsidiary for ~$165 million in June 2026.

Full INGR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IFF drivers: The Food Ingredients sale and the capital return attached to it; Deleveraging from the DuPont merger is essentially complete.
• INGR drivers: Corn costs pass through, so revenue and profit move separately; Texture & Healthful Solutions carries the mix shift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. For INGR, the thermal event at the Argo plant held back volumes and added manufacturing cost through the first half, cutting gross margin to ~23% from ~26% a year earlier and taking US and Canada segment operating income down ~48% year to date.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IFF if you believe its drivers more; INGR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IFF and INGR guides.

IFF. The two revenue figures are not a contradiction: trailing revenue of ~$10.8 billion covers the whole company, while 2026 guidance of ~$7.4 billion to ~$7.6 billion covers only the three segments IFF is keeping, since Food Ingredients and the Soy Crush businesses moved to discontinued operations in the second quarter. Trailing GAAP EPS of ~$1.08 puts the shares near 78 times earnings, a number distorted by amortization and disposal charges, which is why the forward multiple of roughly 25 times is the one most analysts quote. Enterprise value of about $26.6 billion against ~$2.06 billion of trailing credit adjusted EBITDA works out near 13 times, while Food Ingredients is being sold at roughly 8 times its own EBITDA.

INGR. Near ~$105 a share the stock carries about ~11 times trailing earnings and roughly ~9.5 times the midpoint of 2026 adjusted guidance, a visible discount to the branded specialty ingredient houses. That gap prices the commodity half of the business, the Argo disruption and the leverage still to arrive. Reported and adjusted earnings diverge unusually far this year because of the Cabo closure charges, the ~$44 million Pakistan disposal gain and the acquisition hedges, so the ~$9.15 to ~$9.75 reported guide sits well below the ~$10.30 to ~$10.90 adjusted one.

Headline figures (approximate, August 2026): IFF shows revenue (ttm, all businesses) ~$10.8B, fy 2026 sales guidance (continuing operations) ~$7.4B to ~$7.6B, q2 2026 adjusted operating ebitda margin ~20.9%, adjusted eps ex-amortization (first half 2026) ~$1.74; INGR shows market cap ~$6.6B, revenue (ttm) ~$7.2B, net income (ttm) ~$592M, fy 2026 adjusted eps guidance ~$10.30 to ~$10.90.

IFF and INGR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IFF and INGR exposure against your real portfolio. It is not an investment adviser.